SME Times is powered by   
Search News
Just in:   • Modi at UNGA: 10 highlights of India's solutions at 'unparalleled' scale  • Import duty norm relaxed to improve containers availability  • Premium valuations biggest risk to market rally  • Big relief for service sector with SEIS release: FIEO  • Rs 300cr undisclosed income detected by I-T at financing syndicates 
Last updated: 27 Sep, 2014  

Lupin1.Thmb.jpg Lupin to sell skin disease treatment lotion in US

   Top Stories
» Import duty norm relaxed to improve containers availability
» Big relief for service sector with SEIS release: FIEO
» Semiconductor shortage to further impact PV sales in Sep
» Centre to bring new cooperative policy soon: Amit Shah
» Make SEEPZ a world-class facility, says Piyush Goyal
SME Times News Bureau | 24 Sep, 2013
Pharmaceutical major Lupin has signed an agreement with US-based Onset Dermatologics under which it will market the latter's skin disease treatment medicine Locoid Lotion in the American market.

Lupin's US subsidiary, Lupin Pharmaceuticals Inc, has signed the strategic co-promotion agreement with Onset Dermatologics, which allows Lupin exclusive rights to promote Onset's Locoid Lotion (hydrocortisone butyrate 0.1 percent) to paediatricians in the US, the company said in a statement Monday.

Locoid is the most highly prescribed mid-potency steroid brand in the US. The medicine is a corticosteroid indicated for the topical treatment of mild to moderate Atopic Dermatitis (AD) in patients 3 months of age and older.

AD is one of the most common skin disorders in young children and has a prevalence of 10 per cent to 20 per cent in the first decade of life.

It is a chronic illness that requires a multi-faceted treatment strategy in the setting of limited therapeutic options.

Quoting National Institute of Arthritis and Musculoskeletal and Skin Diseases, Lupin said AD, more commonly called eczema, affects 10 to 20 per cent of children in the US and direct health-care costs exceed USD 3 billion.

"We are very pleased with the addition of Locoid Lotion to our Brand portfolio and are committed to bring meaningful products to the US paediatric community," said Vinita Gupta, CEO, Lupin Pharmaceuticals Inc.

Lupin's paediatric portfolio consists of Suprax and Alinia for oral suspension.
Print the Page Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 26 Sep, 2021
  Daily Poll
COVID-19 has directly affected your business
 Can't say
  Commented Stories
» Rajasthan the most unemployed state after Haryana(1)
» Credit monitoring cell to monitor MSME loans(1)
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter